Modulation of Pharmacokinetic and Cytotoxicity Profile of Imatinib Base by Employing Optimized Nanostructured Lipid Carriers

Pharmaceutical Research

Volumn 32, Issue 9, 2015, Pages 2912-2927

  Gupta, Biki ^a   Poudel, Bijay Kumar ^a   Tran, Tuan Hiep ^a   Pradhan, Roshan ^a   Cho, Hyuk Jun ^a   Jeong, Jee Heon ^a   Shin, Beom Soo ^b   Choi, Han Gon ^c   Yong, Chul Soon ^a   Kim, Jong Oh ^a  

^a Yeungnam University   (South Korea)

^b Catholic University of Daegu   (South Korea)

^c Hanyang University   (South Korea)

Author keywords

bioavailability; central composite design; imatinib base; nanostructured lipid carrier; Plackett Burman design

Indexed keywords

ARACHIS OIL; CASTOR OIL; COTTON SEED OIL; IMATINIB; LABRASOL; NANOCARRIER; NANOSTRUCTURED LIPID CARRIER; PHOSPHATIDYLCHOLINE; SESAME SEED OIL; SORBITAN SESQUIOLEATE; SUNFLOWER OIL; UNCLASSIFIED DRUG; DRUG CARRIER; LIPID; NANOMATERIAL; POLYSORBATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG HALF LIFE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MTT ASSAY; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SURFACE PROPERTY; SUSTAINED DRUG RELEASE; THERMOGRAPHY; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSMISSION ELECTRON MICROSCOPY; X RAY DIFFRACTION; ANIMAL; BIOAVAILABILITY; CHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; ORAL DRUG ADMINISTRATION; PROCEDURES; SPRAGUE DAWLEY RAT;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; IMATINIB MESYLATE; LECITHINS; LIPIDS; MALE; NANOSTRUCTURES; PARTICLE SIZE; POLYSORBATES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84938748250     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-015-1673-7     Document Type: Article

References (32)

1. Muller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm. 2002;242:121-8.
2. Joshi MD, Müller RH. Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm. 2009;71:161-72.
3. Liu L, Tang Y, Gao C, Li Y, Chen S, Xiong T, et al. Characterization and biodistribution in vivo of quercetin-loaded cationic nanostructured lipid carriers. Colloids Surf B: Biointerfaces. 2014;115:125-31.
4. Zhang T, Chen J, Zhang Y, Shen Q, Pan W. Characterization and evaluation of nanostructured lipid carrier as a vehicle for oral delivery of etoposide. Eur J Pharm Sci. 2011;43:174-9.
5. Mussi SV, Sawant R, Perche F, Oliveira MC, Azevedo RB, Ferreira LAM, et al. Novel nanostructured lipid carrier co-loaded with doxorubicin and docosahexaenoic acid demonstrates enhanced in vitro activity and overcomes drug resistance in MCF-7/Adr cells [published online ahead of print Feb 13 20014]. Pharm Res. 2014. doi: 10.1007/s11095-013-1290-2.
6. Liu D, Liu Z, Wang L, Zhang C, Zhang N. Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloids Surf B: Biointerfaces. 2011;85:262-9.
7. Zhang XG, Miao J, Dai YQ, Du YZ, Yuan H, Hu FQ. Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancer cells. Int J Pharm. 2008;361:239-44.
8. Taratula O, Kuzmov A, Shah M, Garbuzenko OB, Minko T. Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. J Control Rel. 2013;171:349-57.
9. Zhang XY, Qiao H, Ni JM, Shi YB, Qiang Y. Preparation of isoliquiritigenin-loaded nanostructured lipid carrier and the in vivo evaluation in tumor-bearing mice. Eur J Pharm Sci. 2013;49:411-22.
10. Selvamuthukumar S, Velmurugan R. Nanostructured lipid carriers: a potential drug carrier for cancer chemotherapy. Lipids Health Dis. 2012;11:159. Available from: http://www.lipidworld.com/content/11/1/159.
11. Fang CL, Al-Suwayeh SA, Fang JY. Nanostructured lipid carriers (NLCs) for drug delivery and targeting. Recent Pat Nanotechnol. 2013;7:41-55.
12. Al-Hadiya BMH, Bakheit AHH, Abd-Elgalil AA. Imatinib mesylate. In: Brittain HG, editor. Profiles of drug substances, excipients, and related methodology, Volume 39. Elsevier Inc. p. 265-297. Available from: http://dx.doi.org/ 10.1016/B978-0-12-800173-8.00006-4
13. Gündüz H, Özlü Y, Yal in S. Process for the preparation of imatinib base. US Patent No. US 8,252,926 B2. 2012 Aug 28.
14. Lionberger RA, Lee SL, Lee LM, Raw A, Yu LX. Quality by design: concepts for ANDAs. AAPS J. 2008;10(2):268-76.
15. Poudel BK, Marasini N, Tran TH, Choi HG, Yong CS, Kim JO. Formulation, characterization and optimization of valsartan self-microemulsifying drug delivery system using statistical design of experiment. Chem Pharm Bull. 2012;60(11):1409-18.
16. Dejaegher B, Heyden YV. Experimental designs and their recent advances in set-up, data interpretation, and analytical applications. J Pharm Biomed Anal. 2011;56:141-58.
17. Velpandian T, Mathur R, Agarwal NK, Arora B, Kumar L, Gupta SK. Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples. J Chromatogr B. 2004;804:431-4.
18. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm. 2000;50:161-77.
19. Derringer G, Suich R. Simultaneous optimization of several response variables. J Qual Tech. 1980;12(4):214-9.
20. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005;105(7):2640-53.
21. Baş D, Boyaci IH. Modeling and optimization I: usability of response surface methodology. J Food Eng. 2007;78:836-345.
22. Bezerra MA, Santelli RE, Oliveira EP, Villar LS, Escaleira LA. Response surface methodology (RSM) as a tool for optimization in analytical chemistry. Talanta. 2008;76:965-77.
23. Zhang X, Liu J, Qiao H, Liu H, Ni J, Zhang W, et al. Formulation optimization of dihydroartemisinin nanostructured lipid carrier using response surface methodology. Powder Technol. 2010;197:120-8.
24. Kudarha R, Dhas NL, Pandey A, Belgamwar VS, Ige PP. Box-Behnken study design for optimization of bicalutamide-loaded nanostructured lipid carrier: stability assessment [published online ahead of print May 2, 2014]. Pharm Dev Technol. 2014. doi: 10.3109/10837450.2014.908305.
25. Liu CH, Wu CT. Optimization of nanostructured lipid carriers for lutein delivery. Colloids Surf A Physicochem Eng Asp. 2010;353:149-56.
26. Keshri L, Pathak K. Development of thermodynamically stable nanostructured lipid carrier system using central composite design for zero order permeation of econazole nitrate through epidermis. Pharm Dev Technol. 2013;18(3):634-44.
27. Kalam MA, Sultana Y, Ali A, Aqil M, Mishra AK, Aljuffali IA, et al. Part I: development and optimization of solid-lipid nanoparticles using Box-Behnken statistical design for ocular delivery of gatifloxacin. J Biomed Mater Res Part A. 2013;101A:1813-27.
28. Marasini N, Yan YD, Poudel BK, Choi HG, Yong CS, Kim JO. Development and optimization of self-nanoemulsifying drug delivery system with enhanced bioavailability by Box-Behnken design and desirability function. J Pharm Sci. 2012;101(12):4584-96.
29. Tran TH, Ramasamy T, Truong DH, Shin BS, Choi HG, Yong CS, et al. Development of vorinostat-loaded solid lipid nanoparticles to enhance pharmacokinetics and efficacy against multidrug-resistant cancer cells [published online ahead of print Feb 22, 2014]. Pharm Res. 2014. doi: 10.1007/s11095-014-1300-z.
30. Sofou S. Radionuclide carriers for targeting of cancer. Int J Nanomed. 2008;3(2):181-99.
31. Yang X, Li Y, Li M, Zhang L, Feng L, Zhang N. Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer. Cancer Lett. 2013;334:338-45.
32. Bondì ML, Craparo EF, Giammona G, Cervello M, Azzolina A, Diana P, et al. Nanostructured lipid carriers-containing anticancer compounds: preparation, characterization, and cytotoxicity studies. Drug Deliv. 2007;14:61-7.